131 results about "Immunostimulant" patented technology

Disclosed are methods of augmenting efficacy of oncology therapies by providing reprogrammed cells such as personalized regenerative cells that modulate the tumor microenvironment. In one embodiment, somatic cells are dedifferentiated into OCT-4 expressing cells and endowed with tumor homing properties through culture or gene engineering. Once a stable population of tumor homing cells is established, such cells are made to express immune stimulating agents constitutively, or selectively upon entering the cancer microenvironment. Selective expression of immune stimulatory agents can be induced by exposure to hypoxia, acidosis, immune suppressive signaling or inflammatory signaling.

The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

To provide a novel compound isolated from rice bran extract and a use thereof.SOLUTION: The present invention provides a compound represented by chemical formula (1), an immunoactivator comprising the compound of chemical formula (1), and a humectant comprising the compound of chemical formula (1).SELECTED DRAWING: None

The present invention is directed to a method for treating cancer by delivering lipid-nanoparticles (LNPs) encapsulating immunostimulant mRNA and bispecific antibody mRNA to cancer cells or intratumorally. The method comprising the step of administering mRNA-encapsulated LNPs to a tumor lesion of a subject having cancer. The immunostimulant mRNA-LNP activates immune cells around tumor, which work together with mRNA-LNP encoding bispecific antibody and PBMC to effectively target local and distant metastatic tumors. Preferred immunostimulants are GM-CSF and IL-12, and its combination.

The invention relates to detection of vaccine immune effects, in particular to a Marek's disease virus specificity IFN-gamma sandwich ELISA method and application thereof. The invention provides a Marek's disease virus specific T cell immune stimulator, and the amino acid sequence of the Marek's disease virus specific T cell immune stimulator is shown as SEQ ID NO: 1 or SEQ ID NO: 3. The invention further provides a method for detecting the cellular immune level after Marek's disease vaccine immunization. The Marek's disease virus specific T cell immunostimulant can effectively stimulate cell-mediated immune response, initiate and activate MDV specific T cells, so that the Marek's disease virus specific T cells generate Marek's disease virus specific IFN-gamma, and the Marek's disease virus specific T cell immunostimulant has a good application prospect in Marek's disease vaccine immune level detection.

Disclosed are compounds, compositions, and methods relating to epitope-targeted immunostimulants (EPis), which comprise a synthetic peptide ligand and an antibody-recruiting moiety. The peptide ligand binds an epitope on a target and the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target. Also disclosed are compositions comprising any of the disclosed EPis. Also disclosed are methods of stimulating an immune reaction to a microorganism or other pathogen in a subject where an EPI is administered to the subject. Also disclosed are methods of identifying the peptide ligand by using multi-omic analysis.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

The invention relates to the technical field of biological medicine, and discloses a nano composite adjuvant as well as a preparation method and application thereof. The composite adjuvant mainly comprises a TLR9 agonist CpG ODN, a nanoscale liposome, a cationic lipid DOTAP and a high-efficiency immunologic stimulant QS-21, several adjuvant components are prepared into the stable and uniform nanoscale liposome by adopting a microfluidic synthesis method, CpG is wrapped inside the nanoscale liposome, QS-21 is adsorbed outside the nanoscale liposome, a stable immunologic stimulation compound is formed, and the immunologic stimulant can be used for immunologic detection of the TLR9 agonist CpG ODN, the cationic lipid DOTAP and the high-efficiency immunologic stimulant QS-21. All the components have a remarkable synergistic effect, and are matched with corresponding antigens to generate strong and lasting cellular immune and humoral immune responses.

The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.

The present invention is directed to a method for treating cancer by delivering lipid-nanoparticles (LNPs) encapsulating immunostimulant mRNA and bispecific antibody mRNA to cancer cells or intratumorally. The method comprising the step of administering mRNA-encapsulated LNPs to a tumor lesion of a subject having cancer. The immunostimulant mRNA-LNP activates immune cells around tumor, which work together with mRNA-LNP encoding bispecific antibody and PBMC to effectively target local and distant metastatic tumors. Preferred immunostimulants are GM-CSF and IL-12, and its combination.

Disclosed are compounds, compositions, and methods relating to epitope-targeted immunostimulants (EPIs), which comprise a synthetic peptide ligand and an antibody-recruiting moiety. The peptide ligand binds an epitope on a target and the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target. Also disclosed are compositions comprising any of the disclosed EPIs. Also disclosed are methods of stimulating an immune reaction to a microorganism or other pathogen in a subject where an EPI is administered to the subject. Also disclosed are methods of identifying the peptide ligand by using multi-omic analysis.

The invention discloses an immune agonist and a preparation method thereof, and relates to the technical field of immune agonist preparation, and the preparation method of the immune agonist comprises the following specific steps: S1, preparing a double-target immune agonist monomer; s2, preparing a cationic liposome inner core; s3, biomimetic cell membrane coating; and S4, finished product detection. According to the immune agonist and the preparation method thereof, in the preparation process, a continuous flow microreactor is used for two-step synthesis of a double-target monomer, a segmented precise temperature control mode is matched with microwave strengthening, the reaction period can be shortened, efficient entrapment of the agonist is achieved through a micro-reaction technology, and the problems that a traditional batch method is low in entrapment efficiency and uneven in particle size are solved; in addition, MDC cell membrane extraction is conducted through differential centrifugation, the integrity of the membrane is guaranteed, active targeting of a CD11c marker on the surface of the MDC cell membrane is achieved through a cell biomimetic membrane, and after lipidosome and membrane vesicles with the volume ratio being 3: 1 are fused, the in-vitro BMDC binding rate is increased compared with that of naked lipidosome.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and / or optionally one or more additional anti-cancer agents.

The present invention provides an immunologic stimulant which contains Lactobacillus helveticus, and wherein the Lactobacillus helveticus has three functions: the activation of dendritic cell-like cells, the induction of the production of immunoglobulin A (IgA), and the induction of the production of interleukin-12 (IL-12).

The present invention relates to compositions comprising an inactivated Mycobacterium or an immunogenic fraction thereof, for use in the prevention of an infection in a subject, wherein the infection is selected from the group consisting of a protozoan parasitic infection and a bacterial infection, with the proviso that the infection is not caused by a Mycobacterium.

A pharmaceutical combination comprising (i) a phosphatidylserine (PS) blocker, (ii) an immune stimulant, and (iii) one or more chemotherapeutic agents; compositions and sustained-release formulations comprising the same; and their use in cancer immunotherapy; and a method of preparing a sustained-release formulation.

Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulant selected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and / or immunostimulant may be present as a pharmaceutically acceptable salt. The adjuvant composition may be comprised together with an antigen in an immunogenic composition, such as a vaccine composition, which may be for use to induce an immune response in a subject. Further provided is use of the immunogenic composition to induce an immune response in a subject, particularly an immune response that comprises both a cell-mediated response and a humoral response.

To provide a novel immunostimulator, interferon-α production inducer, or dendritic cell activator derived from a natural product.SOLUTION: Lactiplantibacillus plantarum as Gram-positive bacterium was found to have excellent interferon-α production induction or dendritic cell activation effects.SELECTED DRAWING: Figure 1

The present invention discloses a triterpenic saponin fraction denominated FR, isolated by preparative RP-HPLC from an extract of Quillaja saponaria Molina. FR fraction is characterized by its significant immunostimulant, antibacterial, antiviral and antifungal activity, as well as its cytotoxic effect against tumoral cells.

The application belongs to the application field of selenium polysaccharide, and particularly relates to application of the selenium polysaccharide in preparation of an immune active agent, wherein the selenium polysaccharide is obtained by treating Cyclobalanopsis glauca with exogenous selenium, has good immune activity, can better promote proliferation and phagocytosis of RAW264.7 macrophages, and has a significant advantage in improving the release amount of NO, and the results show that the polysaccharide after exogenous selenium strengthening has better immune activity. Exogenous selenium strengthening obviously improves the characteristics of the selenium polysaccharide in Cyclobalanopsis glauca leaves, and has better potential in antioxidation and immune improvement, and provides data support for further research and utilization.

The invention discloses an application of a penaeus vannamei fatty acid binding protein (FABP) as an immunologic stimulant and an application of the FABP in preparation of drugs for enhancing the immune response capability of crustacean, and aims to enhance the vibrio parahaemolyticus infection resistance of the crustacean by improving the expression level of intracellular antibacterial peptides. Large-area death of crustacean caused by acute hepatopancreatic necrosis (AHPND) is avoided. The amino acid sequence number is E2IH93, the molecular weight is 15495 Dalton, no toxic or side effect exists, the synthesis cost is low, a new way is provided for treatment of crustacean bacterial infection, the ecological balance in the breeding process is not damaged, and the bacillus subtilis is an environment-friendly and efficient bacterial infection defense substance and has important application value.

Disclosed are compounds, compositions, and methods relating to epitope-targeted immunostimulants (EPIs), which comprise a synthetic peptide ligand and an antibody-recruiting moiety. The peptide ligand binds an epitope on a target and the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target. Also disclosed are compositions comprising any of the disclosed EPIs. Also disclosed are methods of stimulating an immune reaction to a microorganism or other pathogen in a subject where an EPI is administered to the subject. Also disclosed are methods of identifying the peptide ligand by using multi-omic analysis.

Disclosed herein are engineered Treg cells comprising a nucleic acid comprising a thermally-inducible promoter operably linked to a polynucleotide encoding an immunostimulatory agent gene. Also included are compositions thereof and methods and kits suitable for use in treating autoimmune diseases. In some embodiments, the method comprises administering a composition comprising engineered T cells. The engineered T cells can comprise thermally actuatable genetic circuits encoding immunostimulatory agents.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

The disclosed method of treating a malignant solid tumor in a subject comprises the steps of administering to the subject an immunomodulatory dose of a radiophosphatide ether metal chelate, a radiohalogenated phosphatide ether, or other targeted radiotherapy (TRT) agent differentially retained in the malignant solid tumor, and treating the malignant solid tumor by systemically administering an immunostimulatory agent to the subject. Immunotherapy is performed in a subject, such as an immune checkpoint inhibitor. In a non-limiting example, a radioactive phospholipid ether metal chelate or radioactive halogenated phospholipid ether has the formula: # imgabs0 # wherein R1 comprises a chelating agent that chelates with a metal atom wherein the metal atom is an alpha, beta or Auger emitting metal isotope having a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is-N + (CH3) 3.

The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and / or immunostimulatory agents to enhance host immune responses.